Hypophosphatemia in dairy cows is thought to be associated with an increased risk of disease and impaired productivity particularly in early lactation. 1 It not only has been linked to decreased feed intake and productivity but is also believed to cause or contribute to periparturient conditions of the dairy cow such as the downer cow syndrome or postparturient hemoglobinuria. 2, 3 The incidence of periparturient hypophosphatemia even in clinically healthy dairy cows is considerable. Metabolic profiling studies reported incidences of subnormal plasma phosphate concentrations ([Pi]) on the day of calving of above 50% and of 10%-15% in the first two weeks of lactation. 1 The relevance of this periparturient hypophosphatemia remains disputed as it is frequently not associated with clinical signs such as recumbency and postparturient hemoglobinuria. It is the reason for which phosphorus (P) supplementation is recommended and practiced particularly in fresh cows. 2, 4, 5 Treatment recommendations published over the past decades often favor IV bolus administration of solutions containing phosphate (Pi) salts. 2, [6] [7] [8] This approach however has raised concerns for several reasons. First in most countries of the world there are no commercial Pi-containing solutions available that are labeled for the parenteral use in farm animals, making this approach an off-label treatment. Products containing P in a form different and not convertible to Pi seem to be unsuitable for the correction of hypophosphatemia. 1, 4 Secondly bolus infusion of Pi-salt solutions results in a pronounced but short lived increase of plasma [Pi] above the reference range. 6 The poor solubility of Pi may result in complexing of Pi with divalent cations such as calcium or magnesium in plasma thereby causing a decline of the plasma calcium ([Ca]) and magnesium concentration ([Mg]), which presents a concern particularly in early lactation. 2, 9 Thirdly the plasma [Pi] returns to baseline values within two to three hours after administration, making this treatment unsuitable to be used as stand-alone treatment of hypophosphatemia. 6 Oral treatment of P-depleted cows with Pi salts slightly delays onset of action when compared with IV treatment but the treatment is easy to administer and has as an effect lasting for 12-24 hours. 6, 9, 10 Currently, a variety of Pi-containing salts are recommended and used for the oral treatment of hypophosphatemia in cattle, but studies comparing these salts in their efficacy to correct hypophosphatemia are scant. 1, 2, 8 Therefore, the objective of this study was to compare different Pi-salts commonly used in the field in their treatment efficacy for the correction of hypophosphatemia in dairy cows. The salts to be compared were monosodium dihydrogen phosphate (NaH 2 PO 4 ), disodium monohydrogen phosphate (Na 2 HPO 4 ), and magnesium phosphate (MgHPO 4 ). We hypothesized that the efficacy for the correction of hypophosphatemia of these salts is primarily driven by their solubility characteristics. We therefore anticipated most rapid and pronounced effects for the most soluble NaH 2 PO 4 followed by Na 2 HPO 4 while a weaker and more delayed effect was expected for the poorly soluble MgHPO 4 .
| M A TER I A LS A N D M ETH OD S

| Animals, housing, and feeding
The national and institutional guidelines for the care and use of experimental animals were followed and all experimental procedures were approved by the Utrecht University Institutional Animal Care and Use Committee (AVD108002016616).
Twelve clinically healthy Holstein Friesian cows in their fourth week of lactation were used for this study. Cows were between 3 and 6.5 years old and in their second to fifth lactation. All animals were healthy on the basis of physical examination despite of pronounced hypophosphatemia. Cows were housed in tie-stalls with rubber bedding covered with saw dust in a temperature controlled environment.
Prior and during the experimental treatment enrolled cows were fed a Total Mixed Ration that was markedly phosphorus deficient, but that otherwise met currently used nutrient recommendations for dry and lactating dairy cows for a period of 8 weeks. 11 The dry cow ration that was offered for 4 weeks before the expected calving date contained 0.13% P in DM and the ration fed after calving contained 0.18% P in DM. The dietary P content was thus 50% below requirement during the late dry period and at least 40% below the recommended daily dietary supply after parturition. 11 Cows were fed and milked twice daily between 0600 and 0700 hours and 1800 and 1900
hours. The daily milk yield during the experimental treatment period ranged between 25 and 32 kg/day, daily feed intake ranged between 13 and 18 kg DM.
| Experimental study
All cows received a sham treatment serving as control and were there- DPi-C max-model and Pi-T max-model were then derived from the respective functions for each treatment group.
| Biochemical analysis
| Data analysis
| Statistical analysis
Results are expressed as mean and SD or as median and interquartile range (IQR) for variables that were not normally distributed. Normality of distribution was checked by Shapiro-Wilk's test for normality distribution and by checking normal probability plots. Log transformations were used wherever appropriate to obtain normal distribution.
Repeated measurements ANOVAs were conducted to determine treatment, time, and interaction of time and treatment effects using an autoregressive model with Cow ID as subject. Post hoc tests were used whenever F-test was significant. Bonferroni-corrected P values were used and a P < .05 was considered statistically significant.
A statistical software package was used for all analyses (SAS 9.2; SAS Institute, Cary, North Carolina).
| RE S U L TS
All cows tolerated the assigned oral treatment well and remained healthy without any apparent adverse effects.
The plasma [Pi]-time curves stratified by group are presented in The ANOVA revealed a significant treatment effect, with all treatment groups differing from control and MgP differing from NaP and Na 2 P. Although the plasma [Pi] in group NaP was numerically higher than in Na 2 P at various time points the difference was not significant at any time. Time effects were apparent in all groups except control.
The plasma [Pi] tended to increase within 30 minutes of treatment in groups NaP and Na 2 P with significantly increased values relative to baseline 60 minutes after treatment (NaP: P 5 .0044; Na 2 P: P 5 .0077).
The Pi-T max was 420 and 360 minutes after treatment with a peak increment of 5.33 mg/dL (1.72 mmol/L) and 4.30 mg/dL (1.39 mmol/L) in group NaP and Na 2 P, respectively ( Table 2 . The AUC-Pi was the largest in group NaP but differed only numerically from group Na 2 P. The AUC-Pi of group MgP was 50% of group NaP. Baseline plasma [Pi] determined in this study were consistent with pronounced hypophosphatemia and without difference between treatment groups, confirming that the dietary P-depletion protocol used before application of the experimental treatment was appropriate to induce hypophosphatemia. A rapid and sustained effect on the plasma
[Pi] was observed for both sodium phosphate salts with significant effects detectable within 1 hour, peak concentrations occurring after six to seven hours and an effect sustained for over 24 hours ( Figure 1 and Table 1 ). In both groups, the low end of the reference range of plasma [Pi] was reached within 2-3 hours and maintained for 24 hours after treatment. Differences between group NaP and Na 2 P were not significant suggesting a similar effect of NaH 2 PO 4 compared with Na 2 HPO 4 . This is remarkable as both salts differ considerably in their solubility characteristics. Na 2 HPO 4 has a relatively low solubility of 7.7 g/dL water 15 compared with NaH 2 PO 4 with 85 g/dL water at 208C. 16 The low sample size of four animals per treatment group in this study likely resulted in insufficient statistical power to reveal the moderate difference between the treatments with NaH 2 PO 4 and Na 2 HPO 4 .
The treatment effect with NaH 2 PO 4 reported in this study differs from results of other studies conducted in cattle having used similar doses of NaH 2 PO 4 . 9, 10 In these studies, a less pronounced effect on Values with different superscript letters within a row were significantly different (P < .05, Bonferroni corrected). C, control, MgP, treatment with MgHPO 4 , NaP, treatment with NaH 2 PO 4 , Na 2 P, treatment with Na 2 HPO 4 .
TABLE 2 Peak increments of plasma Pi concentrations (DPi-C Max-model ) and time to peak increments of plasma Pi concentrations (Pi-T Max-model ) derived from log normal distribution models (f 5 y0 1 ye ence between studies is attributable to the much more pronounced hypophosphatemia in this study that was achieved through a considerably longer duration of dietary P-depletion. The degree of stimulation of enteral Pi-absorption is associated with the degree of P-deprivation. 17 Stronger stimulation of enteral P uptake is therefore likely to have contributed to higher peak plasma [Pi] values and could also explain delayed peaks through prolonged absorption.
Discrepancies between this and other studies also exist for the effect of Na 2 HPO 4 . An older study used Na 2 HPO 4 to treat dairy cows but reported no effect. 8 The lack of effect of oral Na 2 HPO 4 reported in that study might however be attributable to the use of dairy cows that
were not P-deprived, which might have resulted in considerably lower absorption rates of dietary P. Supplementation of large oral doses of P was reported to impair the apparent absorption of Mg in animals that were not P-deficient. 20, 21 It has thus been suggested that in states of limited availability of dietary Mg excessive supply of oral P might increase the risk for hypomagnesemic tetany. 20 In contrast, in states of low dietary Psupply it was found that the supplementation of P can enhance transruminal Mg-absorption in isolated rumen of sheep. 22 In this study, treatment with sodium phosphate salts had no effect on the plasma
[Mg], which suggests that a single treatment with oral monosodium-or disodium phosphate does not cause a relevant disturbance of the Mg balance in treated animals. This is in agreement with an earlier study investigating the effect of a single oral dose of different phosphate salts in hypophosphatemic dairy cows. 10 
| CON CL U S I ONS
In conclusion a single oral treatment with NaH 2 PO 4 or Na 2 HPO 4 providing the equivalent of 60 g P is adequate for the timely correction of hypophosphatemia in cattle. The treatment has a rapid onset of action and a sustained effect. Oral administration of MgHPO 4 has a considerably protracted effect on the plasma [Pi] and is therefore not recommended to be used as drench or bolus in animals requiring rapid correction of blood [Pi] .
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